FinancialContent

Articles published by Novocure

< Previous 1 2 3 4 5 Next >
News headline image
Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Report Third Quarter 2026 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Reports Second Quarter 2026 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Report Second Quarter 2026 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Reports First Quarter 2026 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Report First Quarter 2026 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Participate in 2026 Leerink Global Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
From Novocure
Via Business Wire
Tickers NVCR
News headline image
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Reports Third Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Report Third Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure Reports Second Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
News headline image
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
From Novocure
Via Business Wire
Tickers NVCR
< Previous 1 2 3 4 5 Next >